Annual EBITDA:
$122.27M+$704.76M(+120.99%)Summary
- As of today, ARWR annual EBITDA is $122.27 million, with the most recent change of +$704.76 million (+120.99%) on September 30, 2025.
- During the last 3 years, ARWR annual EBITDA has risen by +$290.36 million (+172.74%).
- ARWR annual EBITDA is now at all-time high.
Performance
ARWR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$50.49M+$209.82M(+131.69%)Summary
- As of today, ARWR quarterly EBITDA is $50.49 million, with the most recent change of +$209.82 million (+131.69%) on September 1, 2025.
- Over the past year, ARWR quarterly EBITDA has increased by +$207.67 million (+132.12%).
- ARWR quarterly EBITDA is now -86.96% below its all-time high of $387.29 million, reached on March 31, 2025.
Performance
ARWR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$122.27M+$207.67M(+243.18%)Summary
- As of today, ARWR TTM EBITDA is $122.27 million, with the most recent change of +$207.67 million (+243.18%) on September 1, 2025.
- Over the past year, ARWR TTM EBITDA has increased by +$704.76 million (+120.99%).
- ARWR TTM EBITDA is now at all-time high.
Performance
ARWR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ARWR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +121.0% | +132.1% | +121.0% |
| 3Y3 Years | +172.7% | +162.2% | +172.7% |
| 5Y5 Years | +240.2% | +204.4% | +240.2% |
ARWR EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +121.0% | -87.0% | +129.5% | at high | +120.2% |
| 5Y | 5-Year | at high | +121.0% | -87.0% | +129.5% | at high | +120.2% |
| All-Time | All-Time | at high | +121.0% | -87.0% | +129.5% | at high | +120.2% |
ARWR EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | $122.27M(+121.0%) | - | - |
| Sep 2025 | - | $50.49M(+131.7%) | $122.27M(+243.2%) |
| Jun 2025 | - | -$159.33M(-141.1%) | -$85.40M(+12.3%) |
| Mar 2025 | - | $387.29M(+348.0%) | -$97.43M(+83.9%) |
| Dec 2024 | - | -$156.18M(+0.6%) | -$606.38M(-4.1%) |
| Sep 2024 | -$582.49M(-202.6%) | -$157.18M(+8.3%) | -$582.49M(-9.9%) |
| Jun 2024 | - | -$171.36M(-40.8%) | -$529.78M(-15.7%) |
| Mar 2024 | - | -$121.67M(+8.0%) | -$457.85M(-60.5%) |
| Dec 2023 | - | -$132.28M(-26.6%) | -$285.35M(-48.2%) |
| Sep 2023 | -$192.51M(-14.5%) | -$104.47M(-5.1%) | -$192.51M(-13.8%) |
| Jun 2023 | - | -$99.43M(-295.6%) | -$169.21M(-20.8%) |
| Mar 2023 | - | $50.84M(+228.9%) | -$140.09M(+4.6%) |
| Dec 2022 | - | -$39.45M(+51.4%) | -$146.78M(+12.7%) |
| Sep 2022 | -$168.09M(-19.4%) | -$81.17M(-15.5%) | -$168.09M(-12.6%) |
| Jun 2022 | - | -$70.31M(-259.3%) | -$149.30M(-37.1%) |
| Mar 2022 | - | $44.14M(+172.7%) | -$108.86M(+39.3%) |
| Dec 2021 | - | -$60.75M(+2.6%) | -$179.33M(-27.4%) |
| Sep 2021 | -$140.77M(-61.4%) | -$62.38M(-108.9%) | -$140.81M(-11.1%) |
| Jun 2021 | - | -$29.87M(-13.4%) | -$126.77M(-13.9%) |
| Mar 2021 | - | -$26.33M(-18.5%) | -$111.32M(-5.2%) |
| Dec 2020 | - | -$22.23M(+54.0%) | -$105.85M(-21.4%) |
| Sep 2020 | -$87.22M(-232.9%) | -$48.34M(-235.5%) | -$87.22M(-209.8%) |
| Jun 2020 | - | -$14.41M(+31.0%) | -$28.15M(-580.6%) |
| Mar 2020 | - | -$20.87M(-480.7%) | $5.86M(-88.3%) |
| Dec 2019 | - | -$3.59M(-133.5%) | $49.91M(-23.9%) |
| Sep 2019 | $65.63M(+228.1%) | $10.72M(-45.3%) | $65.63M(+45.9%) |
| Jun 2019 | - | $19.60M(-15.5%) | $44.97M(+323.2%) |
| Mar 2019 | - | $23.19M(+91.3%) | $10.63M(+140.2%) |
| Dec 2018 | - | $12.12M(+222.0%) | -$26.44M(+48.4%) |
| Sep 2018 | -$51.24M(-58.6%) | -$9.94M(+32.6%) | -$51.24M(-1.7%) |
| Jun 2018 | - | -$14.74M(-6.2%) | -$50.39M(-25.4%) |
| Mar 2018 | - | -$13.88M(-9.5%) | -$40.20M(-28.6%) |
| Dec 2017 | - | -$12.67M(-39.3%) | -$31.26M(+3.2%) |
| Sep 2017 | -$32.31M(+60.7%) | -$9.10M(-99.8%) | -$32.31M(+32.7%) |
| Jun 2017 | - | -$4.55M(+7.9%) | -$47.97M(+22.6%) |
| Mar 2017 | - | -$4.94M(+64.0%) | -$61.94M(+20.0%) |
| Dec 2016 | - | -$13.72M(+44.6%) | -$77.46M(+5.9%) |
| Sep 2016 | -$82.29M(-0.8%) | -$24.76M(-33.7%) | -$82.29M(-2.9%) |
| Jun 2016 | - | -$18.52M(+9.5%) | -$80.01M(-4.3%) |
| Mar 2016 | - | -$20.46M(-10.3%) | -$76.74M(-1.9%) |
| Dec 2015 | - | -$18.55M(+17.5%) | -$75.32M(+7.7%) |
| Sep 2015 | -$81.60M(-72.5%) | -$22.48M(-47.4%) | -$81.60M(-6.5%) |
| Jun 2015 | - | -$15.25M(+19.9%) | -$76.65M(-3.8%) |
| Mar 2015 | - | -$19.04M(+23.3%) | -$73.83M(-12.5%) |
| Dec 2014 | - | -$24.83M(-41.6%) | -$65.60M(-38.5%) |
| Sep 2014 | -$47.30M(-135.2%) | -$17.54M(-41.1%) | -$47.38M(-31.5%) |
| Jun 2014 | - | -$12.42M(-14.9%) | -$36.03M(-27.6%) |
| Mar 2014 | - | -$10.82M(-63.7%) | -$28.23M(-26.3%) |
| Dec 2013 | - | -$6.61M(-6.9%) | -$22.35M(-11.2%) |
| Sep 2013 | -$20.11M(-4.0%) | -$6.18M(-33.5%) | -$20.11M(-6.6%) |
| Jun 2013 | - | -$4.63M(+6.4%) | -$18.86M(+8.5%) |
| Mar 2013 | - | -$4.94M(-13.3%) | -$20.61M(-2.5%) |
| Dec 2012 | - | -$4.36M(+11.6%) | -$20.12M(-4.4%) |
| Sep 2012 | -$19.34M | -$4.93M(+22.7%) | -$19.27M(-12.1%) |
| Jun 2012 | - | -$6.38M(-43.5%) | -$17.19M(-37.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$4.44M(-26.5%) | -$12.51M(-27.4%) |
| Dec 2011 | - | -$3.51M(-23.4%) | -$9.82M(-36.5%) |
| Sep 2011 | -$9.56M(-17.4%) | -$2.85M(-67.2%) | -$7.19M(-8.7%) |
| Jun 2011 | - | -$1.70M(+2.7%) | -$6.61M(+5.5%) |
| Mar 2011 | - | -$1.75M(-97.4%) | -$6.99M(+4.1%) |
| Dec 2010 | - | -$887.00K(+60.9%) | -$7.29M(+14.1%) |
| Sep 2010 | -$8.15M(+50.4%) | -$2.27M(-8.8%) | -$8.49M(+10.1%) |
| Jun 2010 | - | -$2.09M(-1.7%) | -$9.45M(+1.4%) |
| Mar 2010 | - | -$2.05M(+1.5%) | -$9.58M(+10.5%) |
| Dec 2009 | - | -$2.08M(+35.5%) | -$10.71M(+21.3%) |
| Sep 2009 | -$16.44M(+46.3%) | -$3.23M(-45.2%) | -$13.62M(+37.7%) |
| Jun 2009 | - | -$2.22M(+30.0%) | -$21.85M(+25.3%) |
| Mar 2009 | - | -$3.18M(+36.3%) | -$29.25M(+11.0%) |
| Dec 2008 | - | -$4.99M(+56.5%) | -$32.85M(+4.7%) |
| Sep 2008 | -$30.59M(-11.9%) | -$11.46M(-19.0%) | -$34.46M(-0.3%) |
| Jun 2008 | - | -$9.63M(-42.1%) | -$34.36M(+9.3%) |
| Mar 2008 | - | -$6.78M(-2.7%) | -$37.88M(+3.6%) |
| Dec 2007 | - | -$6.60M(+41.9%) | -$39.30M(-6.4%) |
| Sep 2007 | -$27.35M(-39.6%) | -$11.36M(+13.6%) | -$36.94M(-11.6%) |
| Jun 2007 | - | -$13.14M(-60.3%) | -$33.09M(-36.7%) |
| Mar 2007 | - | -$8.20M(-93.2%) | -$24.20M(-22.4%) |
| Dec 2006 | - | -$4.24M(+43.5%) | -$19.77M(-2.2%) |
| Sep 2006 | -$19.60M(-124.8%) | -$7.51M(-76.5%) | -$19.35M(-43.4%) |
| Jun 2006 | - | -$4.25M(-12.9%) | -$13.50M(-8.7%) |
| Mar 2006 | - | -$3.77M(+1.5%) | -$12.42M(-18.0%) |
| Dec 2005 | - | -$3.82M(-131.0%) | -$10.52M(-23.0%) |
| Sep 2005 | -$8.72M(-223.6%) | -$1.66M(+47.8%) | -$8.55M(-2.8%) |
| Jun 2005 | - | -$3.17M(-69.3%) | -$8.32M(-44.8%) |
| Mar 2005 | - | -$1.87M(-0.9%) | -$5.75M(-30.4%) |
| Dec 2004 | - | -$1.86M(-30.2%) | -$4.41M(-63.6%) |
| Sep 2004 | -$2.69M(-2754.0%) | -$1.43M(-140.0%) | -$2.69M(-108.8%) |
| Jun 2004 | - | -$594.10K(-11.9%) | -$1.29M(-81.9%) |
| Mar 2004 | - | -$531.10K(-273.2%) | -$709.40K(-244.2%) |
| Dec 2003 | - | -$142.30K(-529.6%) | -$206.10K(-118.3%) |
| Sep 2003 | -$94.40K(+28.8%) | -$22.60K(-68.7%) | -$94.40K(-39.2%) |
| Jun 2003 | - | -$13.40K(+51.8%) | -$67.80K(+31.0%) |
| Mar 2003 | - | -$27.80K(+9.2%) | -$98.30K(-5.8%) |
| Dec 2002 | - | -$30.60K(-865.0%) | -$92.90K(-5.6%) |
| Sep 2002 | -$132.50K(-29.0%) | $4000.00(+109.1%) | -$88.00K(+5.0%) |
| Jun 2002 | - | -$43.90K(-96.0%) | -$92.60K(-44.2%) |
| Mar 2002 | - | -$22.40K(+12.8%) | -$64.20K(+2.1%) |
| Dec 2001 | - | -$25.70K(-4183.3%) | -$65.60K(+10.0%) |
| Sep 2001 | -$102.70K(-1.1%) | -$600.00(+96.1%) | -$72.90K(+26.0%) |
| Jun 2001 | - | -$15.50K(+34.9%) | -$98.50K(+5.4%) |
| Mar 2001 | - | -$23.80K(+27.9%) | -$104.10K(-0.4%) |
| Dec 2000 | - | -$33.00K(-26.0%) | -$103.70K(-2.1%) |
| Sep 2000 | -$101.60K(-111.2%) | -$26.20K(-24.2%) | -$101.60K(-36.9%) |
| Jun 2000 | - | -$21.10K(+9.8%) | -$74.20K(-6.5%) |
| Mar 2000 | - | -$23.40K(+24.3%) | -$69.70K(-15.2%) |
| Dec 1999 | - | -$30.90K(-2675.0%) | -$60.50K(-104.4%) |
| Sep 1999 | -$48.10K(-100.4%) | $1200.00(+107.2%) | -$29.60K(+3.9%) |
| Jun 1999 | - | -$16.60K(-16.9%) | -$30.80K(-116.9%) |
| Mar 1999 | - | -$14.20K | -$14.20K |
| Sep 1998 | -$24.00K(+56.2%) | - | - |
| Sep 1997 | -$54.80K | - | - |
FAQ
- What is Arrowhead Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Arrowhead Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of ARWR is $122.27M
What is the all-time high annual EBITDA for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high annual EBITDA is $122.27M
What is Arrowhead Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, ARWR annual EBITDA has changed by +$704.76M (+120.99%)
What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of ARWR is $50.49M
What is the all-time high quarterly EBITDA for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high quarterly EBITDA is $387.29M
What is Arrowhead Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, ARWR quarterly EBITDA has changed by +$207.67M (+132.12%)
What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of ARWR is $122.27M
What is the all-time high TTM EBITDA for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high TTM EBITDA is $122.27M
What is Arrowhead Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, ARWR TTM EBITDA has changed by +$704.76M (+120.99%)